The Cytel Blog: Perspectives on Enquiry & Evidence

Founded in 1987 by Cyrus Mehta and Nitin Patel, research scientists at Harvard University and MIT respectively and..

In this edition of the Career Perspectives series, I interview Charles Warne, Associate Director of Biostatistics at..

The issue of delayed treatment effects in immuno-oncology was demonstrated during a FDA-Industry sponsored workshop..

During the design of a clinical trial, many biotechs want to substantially reduce the risk of a good new therapy being..

With the cloud computing power that we have today, we can run simulation of 1000s of designs with each design..

“We found an optimal design in hours that might have taken months to find using standard methods,” reflected Fabien..

Earlier this year, Cytel founder Cyrus Mehta observed that clinical trial design is often treated like an art rather..

For decades, statisticians have cultivated methods to optimize and de-risk clinical trials for strong regulatory..

Medical researchers and public health experts are becoming more reliant on meta-analyses to capture in summary form,..